Literature DB >> 16439682

Epstein-Barr virus nuclear antigen 2 induces FcRH5 expression through CBF1.

Joanne Mohan1, Jessica Dement-Brown, Sabine Maier, Tomoko Ise, Bettina Kempkes, Mate Tolnay.   

Abstract

Fc-receptor homolog 5 (FcRH5) is a recently identified B-cell membrane protein of unknown function. In Burkitt lymphoma cell lines with chromosome 1q21 abnormalities, FcRH5 expression is deregulated, implicating FcRH5 in lymphomagenesis. Epstein-Barr virus infects and immortalizes B cells, and is implicated in the etiology of several tumors of B-cell origin. Overexpression of genes located on 1q21-25 has been proposed as a surrogate for Epstein-Barr virus in Burkitt lymphoma. We now report that Epstein-Barr virus nuclear antigen 2 (EBNA2) markedly induces the expression of the FcRH5 gene, encoded on chromosome 1q21. Induction occurred in the absence of other viral proteins and did not require de novo protein synthesis. EBNA2 lacks a DNA-binding domain and can target responsive genes through the host DNA binding protein CBF1. We show that induction of FcRH5 by EBNA2 is strictly CBF1 dependent, as it was abolished in CBF1-deficient cells. Accordingly, EBNA2 targeted CBF1 binding sites present in the FcRH5 promoter in vivo, as detected by chromatin immunoprecipitation. These results identify FcRH5 as a novel, direct target of EBNA2 that may contribute to the development of Epstein-Barr virus-associated tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16439682     DOI: 10.1182/blood-2005-09-3815

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  11 in total

1.  Cellular target genes of Epstein-Barr virus nuclear antigen 2.

Authors:  Sabine Maier; Gabriele Staffler; Andrea Hartmann; Julia Höck; Karen Henning; Kristina Grabusic; Reinhard Mailhammer; Reinhard Hoffmann; Matthias Wilmanns; Roland Lang; Jörg Mages; Bettina Kempkes
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

Review 2.  Emerging roles for the FCRL family members in lymphocyte biology and disease.

Authors:  F J Li; W J Won; E J Becker; J L Easlick; E M Tabengwa; R Li; M Shakhmatov; K Honjo; P D Burrows; R S Davis
Journal:  Curr Top Microbiol Immunol       Date:  2014       Impact factor: 4.291

3.  Gene expression analysis of whole blood, peripheral blood mononuclear cells, and lymphoblastoid cell lines from the Framingham Heart Study.

Authors:  Roby Joehanes; Andrew D Johnson; Jennifer J Barb; Nalini Raghavachari; Poching Liu; Kimberly A Woodhouse; Christopher J O'Donnell; Peter J Munson; Daniel Levy
Journal:  Physiol Genomics       Date:  2011-11-01       Impact factor: 3.107

4.  Cutting edge: FcR-like 5 on innate B cells is targeted by a poxvirus MHC class I-like immunoevasin.

Authors:  Jessica A Campbell; Randall S Davis; Lauren M Lilly; Daved H Fremont; Anthony R French; Leonidas N Carayannopoulos
Journal:  J Immunol       Date:  2010-06-02       Impact factor: 5.422

5.  Human Fc receptor-like 5 binds intact IgG via mechanisms distinct from those of Fc receptors.

Authors:  Andrea Franco; Bazarragchaa Damdinsuren; Tomoko Ise; Jessica Dement-Brown; Huifang Li; Satoshi Nagata; Mate Tolnay
Journal:  J Immunol       Date:  2013-04-24       Impact factor: 5.422

6.  Fc receptor-like 5 inhibits B cell activation via SHP-1 tyrosine phosphatase recruitment.

Authors:  Christopher L Haga; Götz R A Ehrhardt; Rebecca J Boohaker; Randall S Davis; Max D Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-23       Impact factor: 11.205

7.  Recent Advances in the Pathobiology of Hodgkin's Lymphoma: Potential Impact on Diagnostic, Predictive, and Therapeutic Strategies.

Authors:  Diponkar Banerjee
Journal:  Adv Hematol       Date:  2011-01-18

8.  The EBNA-2 N-Terminal Transactivation Domain Folds into a Dimeric Structure Required for Target Gene Activation.

Authors:  Anders Friberg; Sybille Thumann; Janosch Hennig; Peijian Zou; Elfriede Nössner; Paul D Ling; Michael Sattler; Bettina Kempkes
Journal:  PLoS Pathog       Date:  2015-05-29       Impact factor: 6.823

9.  Developing the IVIG biomimetic, hexa-Fc, for drug and vaccine applications.

Authors:  Daniel M Czajkowsky; Jan Terje Andersen; Anja Fuchs; Timothy J Wilson; David Mekhaiel; Marco Colonna; Jianfeng He; Zhifeng Shao; Daniel A Mitchell; Gang Wu; Anne Dell; Stuart Haslam; Katy A Lloyd; Shona C Moore; Inger Sandlie; Patricia A Blundell; Richard J Pleass
Journal:  Sci Rep       Date:  2015-04-27       Impact factor: 4.379

10.  EBF1 binds to EBNA2 and promotes the assembly of EBNA2 chromatin complexes in B cells.

Authors:  Laura V Glaser; Simone Rieger; Sybille Thumann; Sophie Beer; Cornelia Kuklik-Roos; Dietmar E Martin; Kerstin C Maier; Marie L Harth-Hertle; Björn Grüning; Rolf Backofen; Stefan Krebs; Helmut Blum; Ralf Zimmer; Florian Erhard; Bettina Kempkes
Journal:  PLoS Pathog       Date:  2017-10-02       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.